Janone acquires worldwide, exclusive license for promising treatment of peripheral arterial disease

Janone acquires worldwide, exclusive license for promising treatment of peripheral arterial disease (pad).janone inc - announced a licensing agreement for tv1001sr.janone inc - will begin planning a phase 2b clinical protocol for pad with an expectation to commence phase 2b trials by second half of 2020.janone inc - intends to apply for secondary indication of pad-associated pain as part of its phase 2b trails.janone inc - expects to pursue fda 505(b)(2) pathway for new drug approval, due to an already approved agent associated with tv1001sr..
JAN Ratings Summary
JAN Quant Ranking